Cantor Fitzgerald Has Negative View of CLDX FY2025 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for Celldex Therapeutics in a research report issued on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will post earnings of ($3.67) per share for the year, down from their previous estimate of ($3.61). Cantor Fitzgerald currently has a “Overweight” rating and a $67.00 target price on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.02. The firm had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%.

Several other research firms have also recently issued reports on CLDX. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Friday, February 28th. The Goldman Sachs Group cut their target price on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. Finally, UBS Group began coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They issued a “buy” rating and a $44.00 target price on the stock. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $55.38.

Celldex Therapeutics Price Performance

NASDAQ CLDX opened at $20.67 on Thursday. The stock has a market capitalization of $1.37 billion, a PE ratio of -8.04 and a beta of 1.76. Celldex Therapeutics has a 1 year low of $18.61 and a 1 year high of $49.65. The business’s 50-day moving average is $23.38 and its 200 day moving average is $28.49.

Institutional Trading of Celldex Therapeutics

A number of hedge funds have recently made changes to their positions in CLDX. Creative Planning bought a new stake in shares of Celldex Therapeutics in the 3rd quarter worth approximately $504,000. GSA Capital Partners LLP boosted its position in shares of Celldex Therapeutics by 191.2% in the 3rd quarter. GSA Capital Partners LLP now owns 16,114 shares of the biopharmaceutical company’s stock worth $548,000 after purchasing an additional 10,581 shares in the last quarter. KBC Group NV boosted its position in shares of Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares in the last quarter. Jennison Associates LLC raised its holdings in Celldex Therapeutics by 32.0% in the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after acquiring an additional 321,325 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in Celldex Therapeutics in the 3rd quarter worth approximately $871,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.